MENLO PARK, Calif., Aug. 04, 2016 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the third fiscal quarter and the nine months ended June 30, 2016, and reported on recent corporate developments. Corium’s fiscal year ends on September 30.
“In our third quarter, we made important advances in executing on our business strategy. We achieved key milestones in our Corium-owned Alzheimer’s transdermal product development programs, which represent transformational growth opportunities,” commented
Corium’s Chief Technology Officer Parminder “Bobby” Singh, Ph.D. added, “We were very pleased to receive favorable feedback from the
development of our Corplex Donepezil once-weekly Alzheimer’s patch candidate, and we anticipate initiating the pilot bioequivalence study in the fourth calendar quarter of 2016. We also expect feedback from the
Recent Corporate Developments
- Third quarter revenues up 52% from second quarter — Quarterly revenues returned to levels last achieved in the third quarter of 2015 as the disruption caused by the extended
FTCreview of Teva’s acquisition of Allergan’s generic business, and its impact on our Clonidine TDS product, moved toward resolution. FDAprovides favorable guidance on lead Alzheimer’s program — The
company reported on
May 2that it had received written pre-IND feedback from the FDAthat concurred with the company’s proposed bioequivalence-based clinical development plan for its Corplex Donepezil candidate. Consistent with its handling of Corium’s submission for Corplex Donepezil, the FDAhas advised that a written response to the request for pre-IND guidance on Corplex Memantine will be provided during the quarter ending September 30.
- Preclinical study of optimized once-weekly Corplex Memantine confirms achievement of target dosing — An optimized formulation has successfully delivered the required dose of memantine over seven days in a pig study, with acceptable skin tolerability. Corium plans to conduct a pharmacokinetic study of the optimized formulation in
healthy subjects to confirm sustained delivery over one week.
- Positive Corplex Donepezil results presented at the 2016 Alzheimer’s
Association International Conference(AAIC) in Toronto, Canada— Dr. Singh presented a poster on the full results from a recent Phase 1 clinical trial of once-weekly Corplex Donepezil, Corium’s lead candidate for the treatment of Alzheimer’s disease.
Financial Results for the Quarter and Nine Months Ended June 30, 2016
Corium reported total revenues in the third quarter of fiscal 2016 of $10.6 million, compared with $10.6 million in the third quarter of fiscal 2015, and for the nine-month period ended June 30, 2016, reported total revenues of $25.1 million, compared with $31.7 million in the
same period of fiscal 2015. For the nine-month period, the decrease in total revenues resulted primarily from a decline in contract research and development revenues, as well as a decline in product revenues versus the same period in fiscal 2015. The decrease in contract research and development revenues is primarily the result of several programs advancing into later stages of clinical development, when there are fewer revenue-generating development activities until preparations begin for approval and commercial launch, along with the discontinuation of two development projects in fiscal 2015. The decline in product revenues for the nine-month period in 2016 compared to the same period in 2015 is primarily the result of the lower level of Fentanyl TDS units ordered and shipped, which was partially offset by a slight increase in revenues from Crest® Whitestrips.
Total research and development (R&D) expenses in the third quarter of fiscal 2016 were $8.3 million, compared with $7.6 million in the third quarter of fiscal 2015, and for the nine-month period ended June 30, 2016, total R&D expenses were $24.2 million, compared with $24.0 million in the same period of fiscal 2015. The increase in total R&D expenses primarily reflects Corium’s increased investment in its proprietary product programs, including the advancement of Corium’s two programs for Alzheimer’s disease through Phase 1 clinical trials. This increase was partially offset by the lower level of resources required for contract research and development programs, which corresponds to the lower level of revenues from contract research and development.
General and administrative (G&A) expenses in the third quarter of fiscal 2016 were $3.1 million, compared with $2.8
million in the third quarter of fiscal 2015, and for the nine-month period ended June 30, 2016, G&A expenses were $9.1 million, compared with $8.2 million in the same period of fiscal 2015. The increase in G&A for the 9-month period was primarily attributable to higher personnel costs along with an increase in stock-based compensation expense.
Corium reported a net loss for the third quarter of fiscal 2016 of $7.5 million, or $0.34 per share, compared with a net loss of $5.9 million, or $0.33 per share, in the third quarter of fiscal 2015. For the nine-month period ended June 30, 2016 Corium reported a net loss of $27.4 million, or $1.23 per share, compared with a net loss of $19.8 million, or $1.10 per share, in the same period of fiscal 2015. As of June 30, 2016, there were 22,359,011 shares of Corium common stock outstanding.
Cash and cash equivalents as of June
30, 2016 were $47.4 million.
Conference Call and Webcast Details
Corium will host a conference call today at 5:00 p.m. ET (
website 10 minutes prior to the start of the call to ensure adequate time for any software downloads that may be necessary. A replay of the conference call will be available for two weeks and may be accessed by visiting Corium’s website.
and consumer products with partners
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our business strategy, financial and operating performance, operating costs and expenses, product pipeline, clinical trial and regulatory timing and plans
and associated resource requirements, regulatory pathways for our development programs, the achievement of clinical and commercial milestones, and the advancement of our technologies as well as our proprietary, co-developed and partnered products and product candidates. Forward-looking statements are based on management’s current expectations and projections and are subject to risks and uncertainties, which may cause Corium’s actual results to differ materially from the statements contained herein. Further information on potential risk factors that could affect Corium’s business and its results are detailed in Corium’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed with the Securities and Exchange Commission on May 13, 2016, and other reports as filed from time to time with the Securities and Exchange Commission. Undue reliance should not be placed on
forward-looking statements, especially guidance on future financial or operating performance, which speaks only as of the date they are made. Corium undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.
Corplex™ and MicroCor® are registered trademarks of Corium International, Inc.
|CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS|
|(in thousands, except share and per share data)|
|Three Months Ended June 30,||Nine Months Ended June 30,|
|Contract research and development revenues||1,983||3,505||4,228||9,798|
|Costs and operating expenses:|
|Cost of product revenues||4,626||4,063||12,924||13,369|
|Cost of contract research and development revenues||2,742||4,065||8,601||12,292|
|Research and development expenses||5,516||3,493||15,566||11,670|
|General and administrative expenses||3,116||2,835||9,106||8,192|
|Amortization of intangible assets||168||141||489||464|
|(Gain) / loss on disposal of equipment||—||(5||)||2||2|
|Total costs and operating expenses||16,168||14,592||46,688||45,989|
|Loss from operations||(5,562||)||(3,994||)||(21,583||)||(14,334||)|
|Loss before income taxes||(7,492||)||(5,914||)||(27,373||)||(19,813||)|
|Income tax expense||—||—||3||2|
|Net loss and comprehensive loss||$||(7,492||)||$||(5,914||)||$||(27,376||)||$||(19,815||)|
|Net loss per share attributable to common stockholders, basic and diluted||$||(0.34||)||$||(0.33||)||$||(1.23||)||$||(1.10||)|
|Weighted average shares used in computing net loss per share attributable to common stockholders, basic and diluted||22,321,581||18,116,021||22,254,849||18,073,879|
|CONDENSED BALANCE SHEETS|
|(in thousands, except share amounts)|
|As of June 30,
|As of September 30,
|Cash and cash equivalents||$||47,394||$||72,218|
|Unbilled accounts receivable||517||812|
|Prepaid expenses and other current assets||1,459||1,367|
|Total current assets||56,291||81,760|
|Property and equipment, net||11,139||11,593|
|Debt financing costs, net||599||554|
|Intangible assets, net||7,072||6,837|
|LIABILITIES AND STOCKHOLDERS’ EQUITY|
|Accrued expenses and other current liabilities||3,895||4,091|
|Long-term debt, current portion||69||57|
|Capital lease obligations, current portion||285||820|
|Recall liability, current portion||460||760|
|Deferred contract revenues, current portion||292||134|
|Total current liabilities||8,072||9,814|
|Long-term debt, net of current portion||51,080||49,807|
|Capital lease obligations, net of
|Recall liability, net of current portion||1,971||2,229|
|Deferred contract revenues, net of current portion||3,500||3,500|
|Additional paid-in capital||169,283||166,085|
|Total stockholders’ equity||11,144||35,322|
|TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY||$||75,767||$||100,744|
Investor and Media Contact:
BCC Partners Karen L. Bergmankbergman@bccpartners.com (650) 575-1509 Susan M. Pietropaolospietropaolo@bccpartners.com (845) 638-6290
News Provided by Acquire Media